3,067 Shares in Astrazeneca Plc $AZN Acquired by Vantus Wealth LLC

Vantus Wealth LLC acquired a new position in Astrazeneca Plc (NYSE:AZN) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 3,067 shares of the company’s stock, valued at approximately $538,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AZN. Triumph Capital Management acquired a new position in Astrazeneca in the 3rd quarter worth approximately $25,000. Bangor Savings Bank boosted its stake in shares of Astrazeneca by 102.7% during the 4th quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after buying an additional 154 shares during the period. Eagle Bay Advisors LLC acquired a new stake in shares of Astrazeneca during the 4th quarter valued at $30,000. YANKCOM Partnership acquired a new stake in shares of Astrazeneca during the 4th quarter valued at $31,000. Finally, TFC Financial Management Inc. boosted its stake in shares of Astrazeneca by 3,350.0% during the 4th quarter. TFC Financial Management Inc. now owns 345 shares of the company’s stock valued at $32,000 after buying an additional 335 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on AZN. DZ Bank raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. TD Cowen reissued a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Barclays reissued a “buy” rating on shares of Astrazeneca in a research note on Monday. Finally, JPMorgan Chase & Co. reissued a “buy” rating on shares of Astrazeneca in a research note on Monday. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $205.33.

Astrazeneca Stock Down 3.1%

Astrazeneca stock opened at $179.90 on Tuesday. The company has a market capitalization of $279.01 billion, a P/E ratio of 27.01, a P/E/G ratio of 1.48 and a beta of 0.25. The firm’s fifty day simple moving average is $191.20 and its 200-day simple moving average is $184.28. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. Astrazeneca Plc has a 1-year low of $137.23 and a 1-year high of $212.71.

Astrazeneca (NYSE:AZN) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. The business had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. Sell-side analysts forecast that Astrazeneca Plc will post 10.26 earnings per share for the current fiscal year.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.